Abstract
Heparan sulphate

HS appeared early in metazoan evolution. Most multi-cellular organisms, from simple invertebrates like Hydra up to human beings, have the capacity to produce HS. The biosynthesis of these polysaccharide chains occurs mainly in the Golgi apparatus and involves a complex set of enzymes (Fig. 1) (reviewed by [1-3]). The first step in HS chain biosynthesis is the enzymatic transfer of a xylose (Xyl) residue, from the sugar nucleotide UDP-Xyl, to the hydroxyl group of specific serine residues of the core protein. Potential acceptor serines are localized next to a glycine residue, flanked by one or more acidic residues. Sequential attachment of two galactose (Gal) residues and one glucuronic acid (GlcA) residue to the Xyl completes the synthesis of the tetrasaccharide linkage region (GlcA-Gal-Gal-Xyl-Ser). This linkage region is identical for both HS and CS, the addition of the fifth saccharide determining the nature of the polysaccharide chain that is further made: an N-acetyl glucosamine (GlcNAc) in the case of HS and an N-acetyl galactosamine (GalNAc) in the case of CS. Amino acid determinants or structural domains lying close to the glycosaminoglycan attachment sites in the protein appear to regulate this step of the process
. After attachment of the first GlcNAc residue, further polymerization takes place by alternate addition of GlcA and GlcNAc to the non-reducing end of the growing chain. This process is catalysed by proteins now recognized as members of the exostosin family of tumour suppressors [6] .
The number of repeating GlcA-GlcNAc disaccharide units varies from 50 to 150 units per HS chain. While chain elongation is ongoing, approximately 40-50% of the GlcNAc residues of the nascent polymer are modified into N-sulphoglucosamine (GlcNS)
residues [7] . This N- [7] . Each modification is incomplete, as the enzymes do not modify all the available sugars and each reaction depends on previous reactions. All this results in extensive structural heterogeneity, the macroscopic organization of HS showing a typical 'block structure' ([8] and reviewed by [9] 
) whereby regions of 2-9 highly modified disaccharides (N-sulphated or NS-domain) alternate with longer regions of relatively unmodified disaccharides (N-acetylated or NA-domain). Short mixed sequences, of alternating N-acetylated/N-sulphated (NA/NS) disaccharides, may occur between the NSdomains and NA-domains. Heparin, which is pharmaceutically manufactured from mast cell rich tissues and is often used as a substitute for HS in experiments, may be considered as a single, unusually extended (~15 kD), highly N-and O-sulphated IdoA-rich NS-domain.
Thus, the fine structure of the HS chain ultimately depends on the regulated expression and action of multiple glycosyltransferases, sulphotransferases and an epimerase, which are arrayed in the lumen of the Golgi apparatus. The processes of chain elongation and modification appear to be at least partially coupled [10] . In addition to polymerases and modifying enzymes, a series of cytoplasmic enzymes are needed to form nucleotide sugar (e.g. UDP-GlcA) and nucleotide sulphate (PAPS, which is the sulphate donor substrate), and multiple transporters are needed to import the nucleotides from the cytosol to the lumen of the Golgi apparatus. The assembly process also depends on the availability of GlcNAc or other sugars. In short, the fine structure of the HS chains on a given PG appears to be tissue [8, 11, 12] and cell type specific [13] , and changes in HS composition occur in association with development, aging and pathology [14] [15] [16] . Figure 1 and thoroughly reviewed by [3] ) and (2) sites that consist of relatively common disaccharides. The arrangement of these common substituents in a sequence-specific manner [10] [18] . Initially, the association of FGF2 with HS had been proposed to protect this growth factor from proteolysis and thermal denaturation and to serve as a reservoir of growth factor that can be released by enzymes that degrade HSPGs [19] . However, since 1991, it has become obvious that HSPGs are essential co-receptors for FGF2, which strongly promote FGF2-FGFR1 binding and subsequent activation of the receptor [20, 21] [31] ) and agrin (reviewed by [32] ). Most HS-chains at the cell surface are attached to transmembrane syndecan (reviewed by [33, 34] ) and GPIanchored glypican (reviewed by [35] [43, 44] , others were unable to confirm this claim [45] . Yet [46, 47] 
Molecular properties of human heparanase-1
The heparanase-1 gene (~50kb) is located on human chromosome 4q22 [57] . The single-copy gene is expressed as 5 and 1.7 kb mRNA species, generated by alternative splicing [54, 57] [62] .
It is worth noting that combining (culture media of insect cells containing) individually
Fig. 2 Predicted structure and processing of human heparanase-1. Heparanase-1 is synthesized as an inactive precursor of ~65 kD that subsequently undergoes proteolytic cleavage, yielding ~8 and ~50 kD protein subunits that heterodimerize to form the active enzyme. The protein contains a putative N-terminal signal peptide (SP, Met
-Ala 35 ), a C-terminal hydrophobic region (HR, Pro 515 -Ile 534 ), five cysteine residues (black C's) and six N-linked oligosaccharides (orange balloons). Heparanase-uses a general acid catalysis mechanism for the hydrolysis of the HS-chains, requiring two critical residues, a proton donor (Glu 225 ) and a nucleophile (Glu 343 ) (red asterisks).
expressed subunits fails to produce active protein [60] 
Expression of human heparanase-1
Under normal conditions, heparanase-1 expression is restricted primarily to placental trophoblasts,
Fig. 3 HS-sequences recognized and cleaved by human heparanase-1. (A) One candidate human heparanase-1 cleavage site, as identified by Pikas et al. [70]. The heparin-derived octasaccharide, which binds antithrombin (binding sequence corresponds to units 2-6, between brackets), is cleaved by human heparanase-1 at a single site (arrow), yielding a GlcA at the newly formed reducing terminus (endo-β-D-glucuronidase activity). The 2-O-sulphate group on a hexuronic acid residue located two monosaccharide units away from the cleavage site is essential for substrate recognition (shown in the largest font size). The 3-O-sulphate group on the GlcN residue, required for high affinity binding of antithrombin, but of no particular relevance in the present context, is shown in italics. (B) A target octasaccharide sequence for human heparanase-1, as identified by Okada et al. [73]. Although longer oligosaccharides are most likely better substrates for the cleavage by human heparanase-1, the minimum size required for recognition is only a trisaccharide (indicated between brackets). A highly sulphated structure is crucial for enzyme action, and the GlcNS structure on the reducing side and GlcN(6S) structure on the non-reducing side of the cleavage site are considered as important for the substrate recognition (shown in the largest font size). The additional 2-N-sulphate group on the non-reducing GlcN or 6-O-sulphate group on the reducing GlcN appear to promote cleavage by heparanase-1 (shown in the middle font size). The GlcN 3-O-sulphate structure (shown in italics) promotes cleavage when it resides in a relatively low sulphated sequence but inhibits cleavage when located in a highly sulphated sequence.
blood-borne cells and keratinocytes [53, 54, 74] [75] . Moreover, human ECs that are stimulated with FGF2 [75] , inflammatory cytokines, oxidized LDL or fatty acids [76, 77] [78, 79] .
The heparanase-1 promoter is GC-rich [80] , and appears to be subjected to multiple, both positive and negative controls (schematically presented in Fig. 4) [95] . Pro-heparanase-1 endocytosis was not blocked by the sole addition of mannose-6-phosphate (Man-6-P) [94] . However, pre-incubation of the precursor with heparin partially inhibited binding and completely abolished endocytosis [94] . These results, together with more recent data from the same group [95] [94] , recent reports show that the processing occurs in acidic intracellular compartments [63, 67, 95, 96, 98] .
Cell surface HSPGs are constitutively internalized and degraded [36, 99] [79, 89, 100] or aggressive metastatic disease [100] [101] [102] , and also in the bone marrow plasma of myeloma patients [103] . Additionally, it has been shown that the active enzyme can be secreted from intracellular compartments in response to a proper and effective stimulus. [104] [105] [106] [107] [108] . Yet, this secreted heparanase-1 appears also to be subject to uptake by cells.
. It is generally accepted that endosomal heparanase-1 is responsible for the initial decomposition of internalized HSPGs. However, the predominant (pathological) function of heparanase-1 is commonly attributed to degradation of HS-chains at the cell surface and in the ECM (see next section), a function that would require the presence of cell surface-bound or secreted active heparanase-1. Elevated levels of heparanase-activity have been detected in sera and urine samples of patients suffering from diabetic nephropathy
In blood-borne cells, active heparanase-1 is stored in specific granules, but in response to chemoattractants or inflammatory stimuli it is redistributed to the cell surface and released by degranulation
Recently, we found that this (re-)capture is mediated by the LRP HSPG receptor-complex and by LRP (Vreys et al., our own unpublished results). Thus, the presence of extracellular (active) heparanase-1 seems to be tightly regulated and restricted by at least two independent mechanisms, on one hand by regulated secretion and on the other hand by LRPmediated (re-)uptake.
Human gastric [109] and oesophagus [110, 111] [112] . The amount of nuclear heparanase-1 has been estimated to represent up to ~7% of the total levels found in the cytosol [112] . It should be noted that the presence of HSPGs in the cell nucleus had been reported long before [113] , and nuclear heparanase-1 is claimed to be able to degrade this nuclear HS [112, 114] [115] ); (3) it uses other proteins, e.g. β-and γ-catenin, as suggested by Schubert et al. [112] , or heat shock protein 90, as suggested by Nobuhisa et al. [116] . [117, 118] . This observation was confirmed by the finding that increased expressions of heparanase-1 mRNA and protein correlate with increased heparanase activity and the metastatic capacity of rat and human breast cancer cells [53, 54] . Since then, this correlation has been observed in a variety of human tumour-derived cell lines and tissues, including those of the bladder [119] , pancreas [120] , cervix [121] , colon [122] , ovary [123] , endometrium [124] , prostate [83] , thyroid [125] , liver [126] , oesophagus [110] , stomach [109] , oral cavity [127] , galbladder [128] , nasopharynx [129] , brain [130] , salivary gland [131] and in multiple myeloma [132] and acute myeloid leukaemia [133] . Consistently, as already mentioned above, elevated levels of heparanase-activity have been detected in sera and urine samples of patients suffering from an aggressive metastatic disease [100] [101] [102] . Moreover, several studies show that increased heparanase-1 expression correlates with a reduced post-operative survival time of cancer patients [109, 111, 119-121, 129, 131] [120] , myeloma [132] and breast carcinoma [134] [68, 137] . More rigorous and specific proof for this notion has been provided recently, using an adenovirus-mediated antisense gene-delivery strategy [138] [139] [140] [142] and is suggested to be mediated, at least in part, by β1-integrin cell membrane localization and activation [143] . Addition of pro-heparanase-1 can induce Akt [144] , p38 and Src signalling [145] [134] . However, this study did not address whether a function as survival factor is dedicated to the inactive proform (e.g. activating Akt, which has a well known function in cell survival [146] ) and/or the active heterodimer form (e.g. releasing HS-bound 'active' FGF2 (see next topic), which is known to suppress apoptotic caspase 3 [147] ). [75] . Moreover, a pronounced correlation between heparanase-1 expression and tumour microvessel density has been reported several times [103, 119, 148, 149] . Consistently, in vivo studies reveal that 'on purpose' elevation of the heparanase activity of tumour cells results in tumours that have a significantly higher microvessel density than tumours established from control cells with low heparanase activity [75, 103, 134] . Similar to effects on tumour metastasis, these effects were best demonstrated with a readily secreted and membrane-bound chimeric form of heparanase-1 [135] . Moreover, it has been shown that the anti-cancerous potential of JG3 or PI-88 is not restricted to suppression of the invasive metastatic phenotype, but is also due to suppression of tumour neovascularization [68, 137] [75, 150, 151] . Yet, heparanase-1 may also elicit angiogenic responses, like EC adhesion, migration, invasion and survival, independent of its enzymatic activity (e.g. by activating Akt signalling [144] ). Upregulation of cyclooxygenase-2 (COX-2) [149, 152, 153] and vascular endothelial growth factor (VEGF) [145] [149] . The marked elevation of VEGF expression and secretion in HEK 293-T, human breast carcinoma and rat glioma cells, by overexpression or exogenous addition of heparanase-1, is independent of the enzymatic activity of the enzyme and seems to be mediated by Src family members [145] . Similarly, (inactive) heparanase-1 was found to induce tissue factor expression in vascular endothelial and cancer cells, via the activation of the p38 signalling pathway [154] . Tissue factor not only possesses pro-coagulant activity, but also plays a role in cellular signalling, contributing to tumour growth, survival, metastasis and angiogenesis [155] . Recently, it has been shown that heparanase-1 enhances the synthesis and cell surface shedding of syndecan-1 [156, 157] . The shed ectodomain of syndecan-1 promotes the growth, metastasis and angiogenesis of tumours [158] [156, 157] [159] , and the ability of activated T cells, auto-sensitized to the myelin basic protein, to cause experimental autoimmune encephalomyelitis is closely correlated with their production of heparanase-activity [160] [54, [104] [105] [106] [107] [161] [162] [163] . Consistently, several inhibitors of heparanase-activity (e.g. have been shown to exhibit in vivo antiinflammatory activity in rats [164] and more recently, it has been shown that local in vivo electroporation of anti-heparanase-1 siRNA into the ear skin of mice markedly inhibits the delayed-type hypersensitivity reactivity, which is mainly T-cell mediated [77] .
cancer cells show also nuclear immunostaining for heparanase-1. The latent (~65 kD) and active (~50 kD) forms of human heparanase-1 were claimed to accumulate in the nucleus of non-transfected human breast carcinoma cells (expressing high levels of endogenous heparanase-1) and in the nucleus of glioma cells that were transfected or uploaded with exogenous human heparanase-1
. How heparanase-1 would translocate into the nucleus is not known, and different mechanisms have been suggested: (1) human heparanase-1 contains its own (yet unidentified) nuclear localization signal; (2) it uses HSPGs (its substrates) as vehicle (e.g. a functional nuclear localization signal has been detected in glypicans
The function for heparanase-1 in the nucleus has not been clarified yet, but recent data suggest that its nuclear localization is correlated with a role in cell differentiation (explained in Section 'Normal development').
Involvement of human heparanase-1 in normal and pathological processes Tumour metastasis
The degradation of various constituents of the ECM, including HSPGs, represents a critical step in the process of cancer invasion and metastasis. It has been shown for many years that the metastatic potential of tumour cells is related to their capacity to degrade HS
. More convincing, direct evidence for a role of heparanase-1 in tumour metastasis was provided by the conversion of non-metastatic murine T-lymphoma and melanoma cells into highly metastatic cells, following transfection with human heparanase-1 cDNA [53]. Similar results were obtained upon over-expression of human heparanase-1 in pancreatic cancer
Tumour angiogenesis
, two key regulators of vascular development, represent additional mechanisms by which heparanase-1 may have indirect pro-angiogenic functions. The up-regulation of COX-2 by heparanase-1 in human oesophageal cancer is strongly suppressed by the combined deletion of three transcription factor binding sites (cycling AMP response element , NF-κB and NF-interleukin-6) in the COX-2 promoter, but whether the (extra-or intracellular) precursor or active form of heparanase-1 is required for this process, is not known
. Yet, it remains to be clarified whether syndecan-1 is acted upon at the cell surface, or encounters heparanase-1 along the stimulus-induced syntenin recycling pathway (see above).
Other pathologies
It has been known for many years that the extravasation of leucocytes, during inflammation, is linked to the degradation of HS from ECs and ECMs. Activated platelets can release heparanase-activity
Emerging evidence indicates that heparanase-1 may also be deregulated and play a critical role in the pathogenesis of different kidney disorders. Elevated levels of heparanase-1 protein and activity have been detected in urine of human patients with diabetic nephropathy [79, 89, 100] and in the glomerular epithelial cells and urine of rats with experimental induced nephropathy [78, 165, 166] [172] . Similarly, heparanase-1 expression progressively increases in murine bone marrow-derived cells undergoing osteoblastic differentiation in vitro [173] . Moreover, it has been demonstrated that nuclear heparanase-1 expression is correlated with the expression of differentiation markers in normal oesophageal keratinocytes and in oesophageal cancer tissues [111, 114] and that overexpression of (active) heparanase-1 in the nucleus induces differentiation of leukemia and breast cancer cells in vitro [116, 174] . How nuclear heparanase-1 is involved during these differentiations has not been elucidated yet, but three hypotheses are: (1) affecting the transcriptional regulation associated with, e.g. nuclear HS-bound FGF2 [175] ; (2) [181] and hair growth [177, 182] , both processes requiring an efficient migration and proliferation of keratinocytes and a proper angiogenic response. Consistently, in normal mice, heparanase-1 expression is restricted to keratinocytes in the stratum corneum of the epidermis (probably contributing to epidermal renewal [183] ), as well as in the outer root sheath of a hair follicle [177] . However, during wound healing, heparanase-1 appears in most keratinocytes adjacent to the wound margins [181] and, after depilation, heparanase-1 is expressed in a highly coordinated temporospatial pattern in the hair follicle [182] . Moreover [181, 182] . Consistently, the skin of the transgenic mice shows an increase in vascular density [177] . Finally, haematoxylin/eosin staining of most tissues of the heparanase-1 over-expressing mice revealed no readily detectable histological differences, except for the mammary glands, which showed abundant side branches and alveolar structures, typical of normal pregnant mice [177, 184] .
Heparanase-2
To potentially identify other heparanases, i.e. as members of a larger protein family, the published amino acid sequence of heparanase-1 was used to 
